DISPATCHES FROM THE FRONTIER OF HUMAN LIFE
The first light of a longer human age
Every week, somewhere on Earth, a trial pushes the edge of what a human life can be. We record each one: what was tested, how far it has climbed, and what is still unknown. Every claim is linked to its source.
The Ascent
Every discovery climbs the same five steps
We label each dispatch by how far its evidence has climbed, so a first glimmer is never mistaken for daylight. How to read the evidence
- Lab & animalFirst lightCells or animals only. Most never reach people.
- Phase 1First stepsFirst in humans. Small, mainly safety and dose.
- Phase 2Early signalDoes it work? Hundreds of people, early efficacy.
- Phase 3Weight of manyTested at scale, usually randomized against standard care.
- ApprovedIn the worldA regulator (FDA, EMA, Health Canada) has authorized it.
Latest dispatches
What moved this season
Approvals, phase 3 results and first-in-human signals, newest first. Filter by frontier.
ERAS‑0015 shrank tumours in early pancreatic and lung cancer testing
For forty years the RAS protein was called undruggable. A second molecule built to reach it is now being tested in people.
First treatment approved for the neurological symptoms of type 3 Gaucher disease
A small molecule that crosses the blood-brain barrier, reaching where earlier treatments could not.
First drug shown to help children with infantile-onset Niemann-Pick disease type C live longer
For a disease that once only took, the first treatment that gives back years.
FDA grants accelerated approval to neladalkib for ALK-positive lung cancer after earlier therapy
Each generation of targeted drug reaches further down the same road.
First factor XIa blood thinner approved to cut the risk of a second stroke
A new class of clot prevention, tested on more than twelve thousand people.
First plasmid DNA immunotherapy approved in the US, for a rare HPV airway disease
Small loops of DNA that teach the body to hunt a virus: a new kind of medicine enters the clinic.
Clot removal 24 to 72 hours after a major stroke improved recovery, with more bleeding
The window to save a brain, once measured in hours, is being measured in days.
Remibrutinib cut relapses versus teriflunomide in two phase 3 multiple sclerosis trials
A new oral class against multiple sclerosis, tested on two thousand people across 46 countries.
Retatrutide reduced sleep apnea severity in two phase 3 trials
One weekly injection reshaping the body's metabolism, and with it the quiet emergencies of sleep.
Immunotherapy alone may let some rectal cancer patients skip surgery, radiation and chemotherapy
For a few, the cure may no longer require the knife.
Daraxonrasib doubled median survival in previously treated pancreatic cancer, and the FDA approved it
The first drug to strike RAS across its many mutations has crossed from trial to treatment.
A man with ALS used a brain implant at home for nearly two years to speak and work, unassisted
Thought becomes speech, every day, in an ordinary home. Mind and machine are learning to share a voice.
Why we keep this record
Science and machine are rewriting the terms of a human life. Someone should keep the record, honestly.
We are optimists with receipts. The Long Dawn is lofty about where humanity is going and plain about where each result stands today. Early signals are labeled early. Company claims are labeled as claims. Risks are printed beside the hope.